Rarebase RemarksMar 22, 2023
#5 - Joe Bellucci: High-throughput screening for drug discovery
Our Director of High Throughput Biology, Joe Bellucci, Ph.D., walks us through advances in high-throughput screening and next generation sequencing that have enabled tailored and scalable approaches to rare disease research.
#4 - Clayton Mellina: Engineering and AI in the biotech space
Clayton Mellina is Director of Software Engineering at Rarebase. He is passionate about developing impactful applications of machine learning and computer vision. Before joining Rarebase, Clayton developed industrial computer vision applications such as automated visual inspection for manufacturing at Google Cloud.
A few years ago, Clayton was diagnosed with a rare genetic disorder called NF2, which causes tumors to grow from his nerves. In this episode of Rarebase Remarks, Clayton discusses his personal experience with rare disease and how breakthrough technologies in machine learning and high throughput biology will drive a precision medicine revolution.
#3 - Mike Graglia: Be humble and smart
Onno & Lynsey recently caught up with Mike Graglia, Co-founder and Managing Director of the SynGAP Research Fund (SRF). SRF is a Rarebase collaborator, and Mike is a leading voice in the rare disease advocacy space. We are honored to feature Mike and share his insights on everything from fundraising tactics to prioritizing R&D efforts on behalf of his community.
#2 - Chris Moxham: Drug hunting for rare disease
We are thrilled to bring Chris Moxham, PhD on board as Rarebase’s CSO. Chris is a drug hunter with 25+ years of experience in large pharma and biotech. Prior to joining the Rarebase team, Chris was CSO at Fulcrum Therapeutics, a clinical stage biotech focused on rare diseases, where he was responsible for the full range of drug discovery, translational science and early development activities. Learn more about what motivates Chris’s rare disease research efforts in our second episode.
#1 – Lynsey Chediak: Never give up
Lynsey Chediak is Rarebase’s head of partnerships. She was born with a rare genetic bone and joint disease called arthrogryposis. Formerly, she led the inaugural precision medicine portfolio at the World Economic Forum. She is also the Founder and CEO of a rare disease patient advocacy non-profit, working to increase patient engagement across pediatric hospitals in the USA. Prior to the Forum, she worked on health policy in the California Governor’s Office and in the United Kingdom’s Parliament. She was one of 100 entrepreneurs selected from across the USA for the prestigious Venture for America fellowship.